Maintenance Therapy for NSCLC: Consensus and Controversy.
Nowadays, advanced non-small cell lung cancer (NSCLC) is still an incurable disease. However, recent researches on maintenance therapy have led to considerable progress. Recently, pemetrexed and erlotinib have been approved for maintenance chemotherapy by both the U.S. Food and Drug Administration and European Medicines Agency. However, there are not adequate data to support the maintenance therapy as the standard treatment for advanced NSCLC and there has been no conclusive predictor of who will get benefit from maintenance chemotherapy and what type of maintenance, continuation or switch, is preferred. This article reviews the main studies on maintenance therapy of advanced NSCLC and discusses the results available to date.
Shanghai Lung Cancer Center, Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200030, China.
Shun
S
Lu
Yong-Feng
YF
Yu
Erlotinib; Maintenance therapy; Non-small cell lung cancer; Pemetrexed